OOIR: Observatory of International Research

Papers

(The median citation count of Cancer Journal is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Social Drivers of Cancer Risk and Outcomes Among African American Men	99
Oncology Physician Workforce Diversity	47
PET Imaging of Metabolism, Perfusion, and Hypoxia	42
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	25
Toxicities From Antibody-Drug Conjugates	23
Building a Bridge to Equity in Health and Health Care in Cancer Care	22
Health Care Policy and Disparities in Health	21
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	21
Clinical Evidence Generation During a Pandemic	21
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	20
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	19
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	18
The Principles and Practice of PARP Inhibitor Therapy	16
Stereotactic Body Radiation Therapy	16
Melanoma—Modern Treatment for Metastatic Melanoma	15
Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes	15
Nonoperative Management for Rectal Cancer	15
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy	13
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer	12
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma	12
Germline Predisposition to Myelodysplastic Syndromes	12
Metastatic Melanoma Treatment in Special Populations	12
Diversity in Cancer Care	12
Antibody Drug Conjugates in Multiple Myeloma	12
Prostate Cancer, Race, and Health Disparity	11

Primary Prevention of Cancer	11
Overlooked and Damaging Impact of Structural Racism and Implicit Bias on US Health Care	11
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes	10
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	10
Rectal Cancer—The Only Constant Is Change	10
Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer	10
DNA Damage Repair Inhibitors—Combination Therapies	9
Advances in Stereotactic Body Radiation Therapy for Lung Cancer	9
Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?	9
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	9
Short- and Long-term Repercussions of Vancomycin on Immune Surveillance and the Efficacy of Antitumor Treatments	8
Menopausal Hormone Therapy and Breast Cancer	8
Supportive Care for Patients With Myelodysplastic Syndromes	8
New Metabolomic Insights Into Cancer	8
Role of the Microbiome in Immunotherapy of Melanoma	8
Overview of the Management of Higher-Risk Myelodysplastic Syndromes	8
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance	8
Introduction	8
The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer	8
Updates in the Management of Uveal Melanoma	8
Effective Personalization of Stereotactic Radiosurgery for Brain Metastases in the Modern Era	8
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease	7
Telemedicine and cancer care: Barriers and strategies to optimize delivery: Erratum	7
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia	7
How Far We’ve Come	7
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma	7
Impact of Precision Medicine in Oncology	7
Discovery of Natural Products for Cancer Prevention	7
Telehealth and Technology	6
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma?	6
Current State of Cell Therapies for Genitourinary Malignancies	6
Hormone Replacement Therapy After Breast Cancer	6
Survival of the Fittest	6
Repurposing Drugs for Cancer Prevention	6
Evolving Landscape of Antibody Drug Conjugates in Lymphoma	6
Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms	6
Telemedicine Across the Cancer Care Continuum	6
Estrogen for the Treatment and Prevention of Breast Cancer	6
Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases	5
With Our Powers Combined	5
Severe Lymphopenia Predicts Poorer Survival in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation	5
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development	5
Gene Expression Profiles in Cancers and Their Therapeutic Implications	5
Telemedicine and Cancer Care	5
Impact of Precision Medicine in Oncology	5
Antibody-Drug Conjugates in Myeloid Leukemias	5
The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation	5
Molecular Imaging of Steroid Receptors in Breast Cancer	5
What to Eat for Cancer Prevention	5
Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer	5

The Gut Microbiome and Pancreatic Cancer Development and Treatment	5
Local Excision for Early-Stage Rectal Adenocarcinomas	5
The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment	5
STING Agonists in Head and Neck Squamous Cell Carcinoma	5
Evolution of Response-Based Radiotherapy for Hepatocellular Cancer	4
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?	4
PARP Inhibitors in Pancreatic Cancer	4
Updates in Classification of Myelodysplastic Syndrome	4
Radiopharmaceuticals for Cancer Diagnosis and Therapy	4
Introduction	4
The Clinical Value of Plasma Epstein-Barr Virus DNA as a Tumor Marker in Nasopharyngeal Carcinoma: Prognostic? Yes, But How Can We Best Use It?	4
Epidemiology and Pathogenesis of Myelodysplastic Syndrome	4
Concerns About Compounded Bioidentical Menopausal Hormone Therapy	4
Chimeric Antigen Receptor T-Cell Therapy	4
Digital Health for Oncological Care	4
Beyond the COVID-19 Pandemic	4
Management of Low-Grade Gliomas	4
Adoptive Cell Therapy for Advanced Solid Tumors	4
Effective Image Communication of Hormone Replacement Therapy Risks and Benefits	3
The Utility of Interim Positron Emission Tomography Imaging to Inform Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma	3
Antibody-Drug Conjugates and Tissue-Agnostic Drug Development	3
Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer	3
Fecal Microbiota Transplantation as a Cancer Therapeutic	3
The Role of Circulating Tumor DNA for Management of Patients With Rectal Cancer	3
The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents	3
The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances	3
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia	3
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches	3
Shifting the Landscape of Spine and Non-Spine Bone Metastases	3
Targets for Cancer Prevention: Evolving Methodologies in Basic and Epidemiological Sciences Identify Interrelated Pathways and the Need for Holistic Approaches	3
Advancements in Understanding and Preventing Obesity-Related Colon Cancer	3
Nuclear Medicine Cancer Care—Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer	3
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma	3
Telemedicine and Burnout—How Enhancing Operational Support Can Improve Digital Health Tools	3
Neoantigen-Specific T Cells in Adoptive Cell Therapy	3
Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine	3